Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147

Ítems similars

• Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
  per: Bergenstal, Richard M., et al.
  Publicat: (2013)
• A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
  per: Bergenstal, Richard M., et al.
  Publicat: (2012)
• Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study
  per: Rosenstock, Julio, et al.
  Publicat: (2013)
• Development of new basal insulin peglispro (LY2605541) ends in a disappointing result
  per: Hirose, Takahisa
  Publicat: (2016)
• How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
  per: Muñoz-Garach, Araceli, et al.
  Publicat: (2016)